Interleukin 8 is a
chemokine produced by various immune cells. They promote angiogenesis,
proliferation and development of cancerous cells. The other diseases which are
associated with interleukin 8 are depression, schizophrenia, bipolar disorder,
migraine, Alzheimer’s disease, colitis, rheumatoid arthritis, multiple
sclerosis, asthma, allergic rhinitis, psoriasis, eczema and others.
Interleukin 8 inhibitors therapies have shown improvements
as anti-CXCL8 signalling inhibitors for the treatment of various diseases,
including cancer and inflammatory diseases. Studies demonstrated that interleukin
8 can be indirectly targeted by mitogen activated protein kinase (MAPK)
inhibitors, phosphatidylinositol-3-kinase (PI3K)/AKT inhibitors, and NF-κB
inhibitors while direct targeting can be done by CXCL8 neutralizing antibodies,
and other drug therapies such as Reparixin. Potent effects of interleukin 8
inhibitors therapeutics as chemo-modulators and anti-angiogenics are expected
to treat various tumors.
Request to Get the Sample Pages at:
The report provides a comprehensive understanding of the
pipeline activities covering all drug candidates under various stages of
development, with detailed analysis of pipeline and clinical trials. Pipeline
analysis of drugs by phases includes product description and development
activities including information about clinical results, designations,
collaborations, licencing, grants, technology and others.
